REFERENCES

• GreenbergP.KesslerR.BirnbaumH.The economic burden of depression in the United States: how did it change between 1990 and 2000? J Clin Psych.20036414651475
   Google Scholar
• KesslerR.ChiuW.DernierO.Prevalence, severity, and comorbidity of twelve-month DSM-IV disorders in the National Comorbidity Survey Replication (NCS-R). Arch Gen Psych.200562617627
   PubMed Web of Science ®Google Scholar
• RushAJ.TrivediMH.CarmodyTJ.et al.One-year clinical outcomes of depressed public sector outpatients: a benchmark for subsequent studies. Biol Psychiatry.200456653
   Web of Science ®Google Scholar
• FochtmannLJ.GelenbergAJ.2nd ed. Washington, DC: American Psychiatric Association;Guideline Watch: Practice Guideline for the Treatment of Patients with Major Depressive Disorder.2005
   Google Scholar
• TrivediMH.RushAJ.WisniewskiSR.et al.Evaluation of outcomes with citalopram for depression using measurement-based care in STAR*D: implications for clinical practice. Am J Psychiatry.2006163284016390886
   PubMed Web of Science ®Google Scholar
• QuitkinFM.PetkovaE.McGrathPJ.et al.When should a trial of fluoxetine for major depression be declared failed? Am J Psychiatry.200316073474012668363
   PubMed Web of Science ®Google Scholar
• BauerM.BschorT.PfennigA.et al.WFSBP Task force on unipolar depressive disorders. World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for Biological Treatment of Unipolar Depressive Disorders in Primary Care. World J Biol Psychiatry .200786710417455102
   PubMed Web of Science ®Google Scholar
• RushAJ.STAR*D: what have we learned? Am J Psych.2007164201204
   PubMed Web of Science ®Google Scholar
• WardenDTrivediMHWisniewskiSR.et al.Predictors of attrition during initial (citalopram) treatment for depression: a STAR*D report. Am J Psychiatry.20071641189119717671281
   PubMed Web of Science ®Google Scholar
• OlfsonM.MarcusS.TedeschiM.Continuity of antidepressant treatment for adults with depression in the United States. Am J Psych.2006163101108
   PubMed Web of Science ®Google Scholar
• LesserIM.CastroDB.GaynesBN.et al.Ethnicity/race and outcome in the treatment of depression: results from STAR*D. Med Care.20074510431051 18049344
   PubMed Web of Science ®Google Scholar
• FavaGA.RuiniC.BelaiseC.The concept of recovery in major depression. Psychol Med.20073730731717311684
   PubMed Web of Science ®Google Scholar
• FavaM.RushAJ.WisniewskiSR.et al.A comparison of mirtazapine and nortriptyline following two consecutive failed medication treatments for depressed outpatients: a STAR*D report. Am J Psychiatry.20061631161117216816220
   PubMed Web of Science ®Google Scholar
• TrivediMH.DalyEJ.Measurement-based care for refractory depression: a clinical decision support model for clinical research and practice. Drug Alcohol Depend.200788(suppl 2)S61S7117320312
   PubMed Web of Science ®Google Scholar
• KeitnerGl.RyanCE.MillerIW.NormanWH.Recovery and major depression: factors associated with twelve-month outcome. Am J Psychiatry.1992149112711281636825
   PubMed Web of Science ®Google Scholar
• SimonGE.Von KorffM.BarlowW.Health care costs of primary care patients with recognized depression. Arch Gen Psychiatry.1995528508567575105
   PubMed Web of Science ®Google Scholar
• StahlSM.GradyMM.Differences in mechanism of action between current and future antidepressants. J Clin Psych.2003641317
   Google Scholar
• ThaseMEBlomgrenSL.BirkettMA.ApterJT.TepnerRG.Fluoxetine treatment of patients with major depressive disorder who failed initial treatment with sertraline. J Clin Psychiatry.1997581621 9055832
   PubMed Web of Science ®Google Scholar
• RushAJTrivediMH.WisniewskiSR.et al.Bupropion-SR, sertraline, or venlafaxine-XR after failure of SSRIs for depression. N Engl J Med.20063541231124216554525
   PubMed Web of Science ®Google Scholar
• RushAJ.WisniewskiSR.WardenD.et al.Selecting among second-step antidepressant medication monotherapies: predictive value of clinical, demographic, or first-step treatment features. Arch Gen Psychiatry.20086587088018678792
   PubMed Web of Science ®Google Scholar
• TrivediMH.FavaM.WisniewskiSR.et al.Medication augmentation after the failure of SSRIs for depression. N Engl J Med.20063541243125216554526
   PubMed Web of Science ®Google Scholar
• NierenbergAA.FavaM.TrivediMH.et al.A comparison of lithium and T augmentation following two failed medication treatments for depression: a STAR*D report. Am J Psychiatry.20061631519153016946176
   PubMed Web of Science ®Google Scholar
• McGrathPJ.StewartJW.FavaM.et al.Tranylcypromine versus venlafaxine plus mirtazapine following three failed antidepressant medication trials for depression: a STAR*D report. Am J Psychiatry.200616315311541 16946177
   PubMed Web of Science ®Google Scholar
• RushAJ.ThaseME.DubéS.Research issues in the study of difficultto-treat depression. Biol Psychiatry.20035374375312706958
   PubMed Web of Science ®Google Scholar
• HunterAM.LeuchterAF.MorganML.CookIA.Changes in brain function (quantitative EEG cordance) during placebo lead-in and treatment outcomes in clinical trials for major depression. Am J Psychiatry.20061631426143216877657
   PubMed Web of Science ®Google Scholar
• HunterAM.RavikumarS.CookIA.LeuchterAF.Changes in brain function (QEEG cordance) during placebo lead-in and SCL-90-R symptom dimension changes in MDD during randomized treatment with antidepressant or placebo. Acta Psychiatrics Scandinavica.2009119266273
   PubMedGoogle Scholar
• PriceDD.FinnissDG.BenedettiF.A comprehensive review of the placebo effect: recent advances and current thought. Ann Rev Psychol.20085956559017550344
   PubMed Web of Science ®Google Scholar
• RutherfordBR.RoseSA.SneedJR.RooseSP.Study design affects participant expectations: a survey. J Clin Psychopharmacol.20092917918119512982
   PubMed Web of Science ®Google Scholar
• KrellHV.LeuchterAF.MorganM.et al.Subject expectations of treatment effectiveness and outcome of treatment with an experimental antidepressant. J Clin Psychiatry.2004651174117915367043
   PubMed Web of Science ®Google Scholar
• AikensJE.NeaseDE Jr.NauDP.et al.Adherence to maintenance-phase antidepressant medication as a function of patient beliefs about medication. Ann Earn Med.200532330
   Web of Science ®Google Scholar
• PapakostasGl.FavaM.Does the probability of receiving placebo influence clinical trial outcome? A meta-regression of double-blind, randomized clinical trials in MDD. Eur Neuropsychopharmacol.200919344018823760
   PubMed Web of Science ®Google Scholar
• BeckAT.RushAJ.ShawBF.EmeryG.New York, NY: Guilford Publications;Cognitive Therapy of Depression.1979
   Google Scholar
• GaudianoBA.MillerIW.Dysfunctional cognitions in hospitalized patients with psychotic versus nonpsychotic major depression. Compr Psychiatry.20074835736517560957
   PubMed Web of Science ®Google Scholar
• AbramsonLY.MetalskyGl.AlloyLB.Hopelessness depression: a theory based subtype of depression. Psychol Rev.198996358372
   Web of Science ®Google Scholar
• CandrianM.FarabaughA.PizzagalliDA.et al.Perceived stress and cognitive vulnerability mediate the effects of personality disorder comorbidity on treatment outcome in major depressive disorder: a path analysis study. J Nerv Ment Dis.200719572973717984772
   PubMed Web of Science ®Google Scholar
• AderR.FeltenDL.CohenN.2nd ed. San Diego, CA: Academic Press;Psychoneuroimmunology.1991
   Google Scholar
• AderR.CohenN.Psychoneuroimmunology: conditioning and stress. Ann Rev Psychology.1993445385
   PubMed Web of Science ®Google Scholar
• GinsburgBC.LambRJ.Reinforcement magnitude modulation of ratedependent effects of fluvoxamine and desipramine in the rat. Behav Pharmacol.20081982983519020418
   PubMed Web of Science ®Google Scholar
• BroadbearJH.WingerG.CiceroTJ.WoodsJH.Effects of response contingent and noncontingent cocaine injection on hypothalamic-pituitaryadrenal activity in rhesus monkeys. J Pharmacol Exp Ther.199929039340210381805
   PubMed Web of Science ®Google Scholar
• TarpyRM.New York, NY: McGraw-Hill Humanities/Social Sciences/Langua;Contemporary Learning Theory and Research.1997
   Google Scholar
• BrodyAL.SaxenaS.SilvermanDH.et al.Brain metabolic changes in major depressive disorder from pre- to post-treatment with paroxetine. Psychiatry Res.19999112713910641577
   PubMed Web of Science ®Google Scholar
• CookIA.LeuchterAF.MorganM.et al.Early changes in prefrontal activity characterize clinical responders to antidepressants. Neuropsychopharmacology.20022712013112062912
   PubMed Web of Science ®Google Scholar
• KhanA.ReddingN.BrownWA.The persistence of the placebo response in antidepressant clinical trials. J Psychiatr Res.20084279179618036616
   PubMed Web of Science ®Google Scholar
• MoertelCG.TaylorWF.RothA.TyceFA.Who responds to sugar pills? Mayo Clin Proc.197651961001107683
   PubMed Web of Science ®Google Scholar
• BattermanRC.Methodology of analgesic evaluation: experience with orphenadrine citrate compound. Curr Ther Res Clin Exp.196576396474954890
   PubMed Web of Science ®Google Scholar
• AmanzioM.PolioA.MaggiG.BenedettiF.Response variability to analgesics: a role for non-specific activation of endogenous opioids. Pain.20019020521511207392
   PubMed Web of Science ®Google Scholar
• AmanzioM.BenedettiF.Neuropharmacological dissection of placebo analgesia: expectation-activated opioid systems versus conditioning-activated specific subsystems. J Neurosci1999194844949870976
   PubMed Web of Science ®Google Scholar
• GottesmanII.GouldTD.The endophenotype concept in psychiatry: etymology and strategic intentions. Am J Psychiatry.200316063664512668349
   PubMed Web of Science ®Google Scholar
• HaslerG.DrevetsWC.ManjiHK.CharneyDS.Discovering endophenotypes for major depression. Neuropsychopharmacology.20042917651781 15213704
   PubMed Web of Science ®Google Scholar
• FavaM.RushAJ.AlpertJE.et al.Difference in treatment outcome in outpatients with anxious versus nonanxious depression: a STAR*D report. Am J Psychiatry.2008165342351 18172020
   PubMed Web of Science ®Google Scholar
• NunesEV.LevinFR.Treatment of depression in patients with alcohol or other drug dependence: a meta-analysis. JAMA.20042911887189615100209
   PubMed Web of Science ®Google Scholar
• DuvalF.LebowitzBD.MâcherJP.Treatments in depression. Dialogues Clin Neurosci.2006819120616889105
   PubMedGoogle Scholar
• GouldTD.GottesmanII.Psychiatric endophenotypes and the development of valid animal models. Genes Brain Behav.2006511311916507002
   PubMed Web of Science ®Google Scholar
• MaybergHS.BrannanSK.MahurinRK.et al.Cingulate function in depression: a potential predictor of treatment response. Neuroreport.19978105710619141092
   PubMed Web of Science ®Google Scholar
• PizzagalliD.Pascual-MarquiRD.NitschkeJB.et al.Anterior cingulate activity as a predictor of degree of treatment response in major depression: evidence from brain electrical tomography analysis. Am J Psychiatry.200115840541511229981
   PubMed Web of Science ®Google Scholar
• CanliT.CooneyRE.GoldinP.et al.Amygdala reactivity to emotional faces predicts improvement in major depression. Neuroreport.2005161267127016056122
   PubMed Web of Science ®Google Scholar
• KorbAS.HunterAM.CookIA.LeuchterAF.Rostral anterior cingulate cortex theta current density and response to antidepressants and placebo in major depression. Clin Neurophysiol.20091201313131919539524
   PubMed Web of Science ®Google Scholar
• SavitzJB.DrevetsWC.Imaging phenotypes of major depressive disorder: genetic correlates. Neuroscience.200916430033019358877
   PubMed Web of Science ®Google Scholar
• SchulzPBerneyP.Clinicians' predictions of patient response to psychotropic medications. Dialogues Clin Neurosci.2004 610511122033598
   PubMedGoogle Scholar
• PerlisRH.losifescuDV.RenshawPF.Biological predictors of treatment response in affective illness. Psychiatr Clin North Am.20032632334412778836
   PubMed Web of Science ®Google Scholar
• KimH.LimSW.KimS.et al.Monoamine transporter gene polymorphisms and antidepressant response in Koreans with late-life depression. JAMA.20062961609161817018806
   PubMed Web of Science ®Google Scholar
• McMahonFJ.BuervenichS.CharneyD.et al.Variation in the gene encoding the serotonin 2A receptor is associated with outcome of antidepressant treatment. Am J Hum Genet.20067880481416642436
   PubMed Web of Science ®Google Scholar
• PerlisRH.MoorjaniP.FagernessJ.et al.Pharmacogenetic analysis of genes implicated in rodent models of antidepressant response: association of TREK1 and treatment resistance in the STAR*D study. Neuropsychopharmacology.2008332810281918288090
   PubMed Web of Science ®Google Scholar
• AnguelovaM.BenkelfatC.TureckiG.A systematic review of association studies investigating genes coding for serotonin receptors and the serotonin transporter: II. Suicidal behavior. Mol Psychiatry.2003864665312874600
   PubMed Web of Science ®Google Scholar
• PerlisRH.Patrick.A.SmollerJW.WangPS.When is pharmacogenetic testing for antidepressant response ready for the clinic? A cost-effectiveness analysis based on data from the STAR*D study. Neuropsychopharmacology.2009342227223619494805
   PubMed Web of Science ®Google Scholar
• MalhotraAK.MurphyGM Jr. Kennedy JL. Pharmacogenetics of psychotropic drug response. Am J Psychiatry.200416178079615121641
   PubMed Web of Science ®Google Scholar
• GottesmanI.ShieldsJ.New York, NY: Academic Press;Schizophrenia and Genetics: a Twin Study Vantage Point.1972
   Google Scholar
• NierenbergAA.McLeanNE.AlpertJE.WorthingtonJJ.RosenbaumJF.FavaM.Early nonresponse to fluoxetine as a predictor of poor 8-week outcome. Am J Psychiatry.1995152150015037573590
   PubMed Web of Science ®Google Scholar
• RojoJE.GibertK.CoboJ.Rodriguez-CanoE.VallejoJ.Onset of antidepressant action: a pharmacological question? Hum Psychopharmacoi.200520425433
   PubMed Web of Science ®Google Scholar
• TaylorMJ.FreemantleN.GeddesJR.BhagwagarZ.Early onset of selective serotonin reuptake inhibitor antidepressant action. Arch Gen Psychiatry.2006631217122317088502
   PubMed Web of Science ®Google Scholar
• PapakostasGl.PerlisRH.ScaliaMJ.PetersenTJ.FavaM.A meta-analysis of early sustained response rates between antidepressants and placebo for the treatment of major depressive disorder. J Clin Psychopharmacoi.2006265660
   PubMed Web of Science ®Google Scholar
• StewartJW.QuitkinFM.McGrathPJ.et al.Use of pattern analysis to predict differential relapse of remitted patients with major depression during 1 year of treatment with fluoxetine or placebo. Arch Gen Psychiatry.1998553343439554429
   PubMed Web of Science ®Google Scholar
• NierenbergAA.QuitkinFM.KremerC.et al.Placebo-controlled continuation treatment with mirtazapine: acute pattern of response predicts relapse. Neuropsychopharmacology.2004291012810214997172
   PubMed Web of Science ®Google Scholar
• SzegediA.JansenWT.van WilligenburgAP.et al.Early improvement in the first 2 weeks as a predictor of treatment outcome in patients with major depressive disorder: a meta-analysis including 6562 patients. J Clin Psychiatry.20097034435319254516
   PubMed Web of Science ®Google Scholar
• KnottVJ.TelnerJl.LapierreYD.et al.Quantitative EEG in the prediction of antidepressant response to imipramine. J Affect Disord.1996 391751848856421
   PubMed Web of Science ®Google Scholar
• UlrichG.HaugH-J.FahndrichAcute versus chronic EEG effects of maprotiline- and in clomipramine-treated depressive inpatients and the prediction of therapeutic outcome. J Affect Disord.1994322132177852663
   PubMed Web of Science ®Google Scholar
• UlrichG.HaugH.StieglitzR.FahndrichE.Are there distinct biochemical subtypes of depression? EEG characteristics of clinically defined on-drug responders and non-responders. J Affect Disord.1988151811852975689
   PubMed Web of Science ®Google Scholar
• LeuchterAF.UijtdehaageSH.CookIA.et al.Relationship between brain electrical activity and cortical perfusion in normal subjects. Psychiatry Res.19999012514010482384
   PubMed Web of Science ®Google Scholar
• AsadaH.FukudaY.TsunodaS.et al.Frontal midline theta rhythms reflect alternative activation of prefrontal cortex and anterior cingulate cortex in humans. Neurosci Lett.1999274293210530512
   PubMed Web of Science ®Google Scholar
• LeuchterAF.CookIA.MarangellLB.et al.Comparative effectiveness of biomarkers and clinical indicators for predicting outcomes of SSRI treatment in Major Depressive Disorder: results of the BRITE-MD study. Psychiatry Res.200916912413119712979
   PubMed Web of Science ®Google Scholar
• LeuchterAF.CookIA.GilmerWS.et al.Effectiveness of a quantitative electroencephalographs biomarker for predicting differential response or remission with escitalopram and bupropion in Major Depressive Disorder. Psychiatry Res.200916913213819709754
   PubMed Web of Science ®Google Scholar
• CookRJ.SackettDL.The number needed to treat: a clinically useful measure of treatment effect. BMJ.19953104524547873954
   PubMed Web of Science ®Google Scholar
• SinclairJC.CookRJ.GuyattGH.et al.When should an effective treatment be used? Derivation of the threshold number needed to treat and the minimum event rate for treatment. J Clin Epidemiol.20015425326211223323
   PubMed Web of Science ®Google Scholar
• PapakostasGlThaseMEFavaMet al.Are antidepressant drugs that combine serotonergic and noradrenergic mechanisms of action more effective than the selective serotonin reuptake inhibitors in treating major depressive disorder? A meta-analysis of studies of newer agents. Biol Psychiatry.2007621217122717588546
   PubMed Web of Science ®Google Scholar
• AltarCA.VawterMP.GinsbergSD.Target identification for CNS diseases by transcriptional profiling. Neuropsychopharmacology.200934185418923405
   PubMed Web of Science ®Google Scholar
• TanisKQ.DumanRS.Intracellular signaling pathways pave roads to recovery for mood disorders. Ann Med.20073953154417852035
   PubMed Web of Science ®Google Scholar
• BegemannM.SarginD.RossnerMJ.et al.Episode-specific differential gene expression of peripheral blood mononuclear cells in rapid cycling supports novel treatment approaches. Mol Med.20081454655218552976
   PubMed Web of Science ®Google Scholar
• IgaJ.UenoS.YamauchiK.et al.Serotonin transporter mRNA expression in peripheral leukocytes of patients with major depression before and after treatment with paroxetine. Neurosci Lett.2005389121616055263
   PubMed Web of Science ®Google Scholar
• IgaJ.UenoS.YamauchiK.NumataS.et al.Gene expression and association analysis of LIM (PDLIM5) in major depression. Neurosci Lett.200640020320716595163
   PubMed Web of Science ®Google Scholar
• IgaJ.UenoS.YamauchiK.et al.Gene expression and association analysis of vascular endothelial growth factor in major depressive disorder. Prog Neuropsychopharmacol Biol Psychiatry.20073165866317257729
   PubMed Web of Science ®Google Scholar
• IgaJ.UenoS.YamauchiK.et al.Altered HDAC5 and CREB mRNA expressions in the peripheral leukocytes of major depression. Prog Neuropsychopharmacol Biol Psychiatry.20073162863217258370
   PubMed Web of Science ®Google Scholar
• IgaJ.UenoS.OhmoriT.Molecular assessment of depression from mRNAs in the peripheral leukocytes. Ann Med.20084033634218484345
   PubMed Web of Science ®Google Scholar
• SunX.YoungLT.WangJF.et al.Identification of lithium-regulated genes in cultured lymphoblasts of lithium responsive subjects with bipolar disorder. Neuropsychopharmacology.20042979980414735134
   PubMed Web of Science ®Google Scholar
• TangY.GlauserTA.GilbertDL.et al.Valproic acid blood genomic expression patterns in children with epilepsy - a pilot study. Acta Neurol Scand.200410915916814763951
   PubMed Web of Science ®Google Scholar